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PENILAIAN PENGHALANG RESEPTOR ANGIOTENSIN II UNTUK
FORMULARI UBAT MENGGUNAKAN ALAT ANALITIKAL
PENSKORAN OBJEKTIF
ABSTRAK
Satu kajian menilai ubat Penghalang Reseptor Angiotensin II (ARBs) untuk
formulari ubat-ubatan dengan menggunakan Alat Analitikal Pengukur Penskoran
Objektif (SAT) untuk memilih ARBs secara rasional supaya ubat dapat dimasukkan
atau dikecualikan daripada formulari ubat-ubatan Kementerian Kesihatan Malaysia.
Lazimnya, sekumpulan doktor pakar yang berpengalaman akan dilantik oleh
Kementerian Kesihatan Malaysia untuk mengendalikan pilihan ubat dalam suatu
masa yang tertentu. Akan tetapi, SAT yang dicadangkan menilai ubat secara objektif
berdasarkan kriteria dan pemberat relatif supaya dapat disesuaikan dengan
kepentingan relatif sub-kriteria. Cara peruntukan skor yang digunakan dalam SAT
membuatkannya amat objektif dan konsisten. Banyak langkah dan perancangan
telah dilakukan untuk menetapkan kriteria dan sub-kriteria yang bersesuaian dengan
penyakit berkenaan dan menentukan skor berdasarkan kepentingan relatif. Kriteria
utama yang dipertimbangkan adalah keselamatan, kualiti, efikasi dan penjimatan kos.
Semua ini ditukarkan kepada format kajian soal selidik. Semua maklumat dan data
dikumpulkan melalui kaji soal selidik yang diedarkan dengan sendiri kepada
pegawai perubatan dan doktor pakar dari hospital kerajaan iaitu Hospital Tengku
Ampuan Rahimah, Hospital Kuala Lumpur, Hospital Selayang, Hospital Serdang,
Pusat Perubatan Universiti Malaya dan Institusi Jantung Negara. Analisis statistik
data ARBs yang dikendalikan menunjukkan terdapat beberapa ubat ARBs dalam
urutan pemilihan ARBs oleh para doktor mungkin dipengaruhi oleh bidang
xv
kepakaran, kelulusan tempatan atau luar negara, dan jantina. Susunan urutan
pemilihan ubat ARBs berdasarkan skor mengikut keutamaan dari atas ke bawah
adalah seperti berikut: Telmisartan (802.2±76.7) ≈ Irbesartan (796.5±65.0) ≈
Losartan (792.9±66.6), Valsartan (719.2±80.5) ≈ Candesartan (734.8±82.5),
Olmesartan (671.0±74.6) dan Eprosartan (600.0 [63.0]). Walau bagaimanapun,
urutan pemilihan ubat ARBs yang diperolehi daripada SAT adalah berbeza dengan
data penggunaan ubat ARBs di Hospital Serdang. Urutan menurun mengikut
keutamaan pemilihan ubat ARBs di Hospital Serdang adalah Losartan, Telmisartan,
Valsartan dan Irbesartan. Perbezaan urutan pemilihan ini adalah disebabkan oleh
batasan tempatan yang diimplimentasikan oleh hospital masing-masing. Penjimatan
kos ARBs yang paling tinggi di hospital kerajaan ialah Irbesartan dan dituruti oleh
Losartan dan Telmisartan. Kajian ini menekankan penggunaan SAT untuk
mengurangkan jumlah ubat-ubatan yang harus dimasukkan dalam formulari ubat,
menilai penjimatan kos ubat-ubatan, memudahkan keputusan dibuat melalui
peruntukan skor untuk kriteria tertentu dan membantu membezakan ubat-ubatan
yang mempunyai ciri-ciri yang sama. Secara keseluruhannya, SAT mempunyai
potensi untuk melengkapkan kaedah tradisional formulari ubat-ubatan kerana SAT
berkesan untuk membantu membuat keputusan yang cepat terutamanya dalam
kecemasan dan untuk mengurangkan inventori ubat-ubatan.
xvi
EVALUATION OF ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS)
FOR DRUG FORMULARY USING OBJECTIVE SCORING ANALYTICAL
TOOL
ABSTRACT
A study into the evaluation of Angiotensin II Receptor Blockers (ARBs) for drug
formulary using an objective Scoring Analytical Tool (SAT) was conducted to
assess and carry out rational selection of the ARBs to be included or omitted in the
Malaysian Ministry of Health (MOH) Drug Formulary. Traditional MOH Drug
Formulary usually conducts drug selection employing a small group of senior who
are very experienced specialists to conduct this drug selection over a period of time.
In contrast, the proposed SAT evaluated the drugs objectively according to criteria
and relative weightage to match the relative importance of the sub-criteria. The
allocation of scores made the method very objective and consistent. Much
preparatory work was carried out to pre-set the criteria and sub-criteria to match the
diseases concerned and to assign scores based on the relative importance. The main
criteria under consideration were safety, quality, cost and efficacy. All these were
converted to questionnaires format. Data and information were collected through
self administered questionnaires that were distributed to pre-qualified medical
doctors and specialists from the established government hospitals namely Tengku
Ampuan Rahimah Hospital, Kuala Lumpur Hospital, Selayang Hospital, Serdang
Hospital, University Malaya Medical Centre and National Heart Institute. Statistical
analysis of the data carried out showed certain ARBs order of preference trend of the
participants which may be influenced by field of specialisation, whether local or
overseas graduate and even gender. Descending order of preference based on scores
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was Telmisartan (802.2±76.7) ≈ Irbesartan (796.5±65.0) ≈ Losartan (792.9±66.6),
Valsartan (719.2±80.5) ≈ Candesartan (734.8±82.5), Olmesartan (671.0±74.6) and
lastly Eprosartan (600.0 [63.0]). Even equating the drug preference trending data
obtained from SAT to the hospital usage database in Serdang Hospital did show that
there were differences in trending of drug preference which in descending order
were Losartan, Telmisartan, Valsartan and Irbesartan. Differences occurred due to
localised restriction imposed by the respective hospitals. The most cost saving ARBs
for hypertension in government hospitals was Irbesartan and followed by Losartan
and Telmisartan. This study emphasises the usefulness of SAT which included
reducing the number of drugs to be kept in the formulary, assessing cost saving of
drugs, score allocation of criteria helped decision making easier and helping to
differentiate drugs where the properties of the drugs were quite similar. On the
whole SAT has the potential to complement the traditional or conventional method
as it is effective in aiding decision making especially in reducing the inventory and
urgent drug decision.
1CHAPTER ONE
INTRODUCTION
1.1 Background
A formulary system is a process whereby the medical staff of an institution, working
through a Drug and Therapeutics Committee, evaluates and selects the numerous
available drug products that are considered most efficacious, safe and cost effective.
A good formulary system not only involves selection of appropriate drugs but also
provides drug use evaluation to enhance quality of care for patients, ensures
treatment protocol and procedures are up to date and consistent with optimal
therapeutics and continuously improve quality of care through monitoring, reporting
and analysis of adverse results of drug therapy (Laing & Tisocki, 2004; Savelli et al.,
1996). Woodhouse (1994) defined main aims of a formulary are to encourage
clinically effective and cost-effective prescribing that restrict the range of medicines,
allow prescribers to increase their familiarity with a smaller number of choices,
favor generic substitution, prevent relatively untried medicines from getting into
uncontrolled widespread use and aid in cost containment.
A drug formulary is a manual containing clinically oriented summaries of
pharmacological information of selected drugs, administrative and regulatory
information pertaining to the prescribing and dispensing of drugs (Savelli et al., 1996;
Quick et al., 1997). As a matter of fact, the World Health Organisation (WHO)
Model Formulary (Laing & Tisocki, 2004) has already made available a practical
guide on how to develop a national formulary so as to provide objective unbiased
2information to health workers in a country and to promote safe, effective and
rational use of medicines.
The main reason for developing a formulary is to promote rational prescribing and to
limit costs (Duerden & Walley, 1999; Avery et al., 1997). However, it should be
noted here that rational prescribing might even lead to increased drug costs.
Furthermore, the cheapest drug doesn’t always become the drug of choice. On the
other hand, there is a myth indicating that expensive drug is more superior to its
competitor and therefore, the newer and expensive drug is always been pushed into
the formulary by the pharmaceutical industries as well as the prescribers. Evidence
that introduction of formulary improves quality of prescribing is limited but a few
number of cases do show cost savings (Duerden & Walley, 1999). Rational drug use
was defined by World Health Organisation (WHO, 1985), as “patients receive
medication appropriate to their clinical needs, in doses that meet their own
individual requirements, for an adequate period of time, and at the lowest cost to
them and their community”. Irrational or non rational use is the use of medicines in
a way that is not compliant with rational use as defined. One of the core
interventions to promote rational drug use is through implementing Drugs and
Therapeutic Committee (DTC) in districts and hospitals. The DTC should represent
all the major specialists and be independent and must declare any conflict of interest,
to be free from biasness (WHO, 2002).
Developing of drug formulary is a continuous and on-going process due to constant
changes in information about drugs and pharmacological practice. It is an important
3process especially updating and monitoring but it is time consuming. The Malaysian
MOH Formulary is an example of such a slow traditional process that generally
employs the seniority and expertise of just a handful of specialists to oversee the
tasks of evaluating the drugs to be approved or omitted from the common lists. Over
recent years many tools have been developed and nowadays, there are many
decision making tools available which can help to speed up the process of evaluation
and selection of drug in the formulary. It is not practical for those involved in the
drug evaluation and selection to delay important decision making especially on life
saving drugs. The decision making tool must enable drugs to be assessed in a more
consistent and reproducible manner. The tool should be objective and exclude
subjective factors such as emotional factors, commercial influence or financial
interest in seeing a drug included or be excluded as much as possible and be
transparent especially on criteria and weighting decisions.
A few drug selection methods with scores have been developed and used worldwide
for formulary purposes such as Comparative Utilisation of Resources Evaluation
Model or CURE Model (Karr, 2000), System of Objectified Judgment Analysis or
SOJA (Janknergt & Steenhoek 1997), Pharmaceutical Product Drug Differentiation
Evaluation Model or PPDDEM (Karr, 1994) and Ranking Model (Bochner et al.,
1994). PPDDEM, CURE and SOJA models of drug selection focus on the way in
which the products are differentiated from each other within the same therapeutic
class such as efficacy, safety, side effect, patient compliance, outcome data, duration
of effects, price or route of administration. The development of the Scoring
Analytical Tool (SAT) which is the main focus of this paper, will involve essentially
selection of group of drugs which requires evaluation, identification of the relevant
4criteria for that group of drugs which can be used to compare competing or similar
drugs, assigning a weighting score to each criteria according to its degree of
importance in the evaluation process. The more important criteria will have a higher
relative weight. Scores for each drug are added up and drugs with the highest total
score will be the preferred drugs for formulary inclusion.
The group of drugs to be focused for the development of the scoring tool for
evaluating or selection of drugs is Angiotensin II Receptor Blockers (ARBs),
hypertensive drugs. ARBs were introduced in the market in 1995 as a new drug class
for hypertension after proving efficacy in lowering blood pressure. ARBs work by
targeting the Renin Angiotensin-Aldosterone System (RAAS) which is the regulator
of blood pressure homeostasis. Activation of RAAS will result in the release of renin
from the juxtaglomerular complex of the nephron which converts Angiotensinogen
into Angiotensin I. Next, either Angiotensin Converting Enzyme or a non-specific
chymase generates Angiotensin II from Angiotesin I. Angiotensin II increases the
blood pressure by three distinct mechanisms i.e. a) increases peripheral vascular
resistance; b) stimulates release of Aldosterone from the adrenal medulla which
induces sodium and water retention; c) causes smooth muscle cell proliferation and
hypertrophy, further enhancing vascular tone. ARBs interfere with the RAAS by
selectively blocking the binding of Angiotensin II to its receptor subtype 1 (AT1).
This selective blockage antagonises the effects of Angiotensin II at the target site,
regardless of the pathway through which it was formed (Givertz, 2001; Rodger &
Patterson, 2001; Burnier, 2001).
5Table 1.1: Pharmacokinetic parameters of ARBs
Route of
Elimination (%)
Drug Pro-drug Maximal
Onset
(week)
T1/2
(hr)
Bioavailability
(%)
Food Effect
(AUC %)
P450
Metabolism
Renal Hepatic
Trough: Peak Ratio
%
Candesartan Yes 2-4 9 15 No No 33 67 80
Eprosartan No 3 5-9 13 Yes No 7 90 67
Irbesartan No 2 12-20 60-80 No No 20 80 >60
Losartan Yes 2-3 2 33 No Yes 35 60 58-78
Olmesartan Yes 2 13 26 No No 35-50 50-65 51.8-79.1
Telmisartan No 3 24 42-58 No No 0.5 98 >97
Valsartan No 2 6 40-50 Yes No 13 83 69-76
6The pharmacokinetics of ARBs (Drug Facts and Comparisons, 2001; Rodger &
Patterson, 2001; Schwocho & Mansonson, 2001) are listed in Table 1.1. All the
ARBs exhibit distinctive pharmacokinetics profiles (Song & White, 2001). Losartan
and Candesartan are pro-drugs and their antihypertensive activities are due to their
metabolites. Candesartan is activated in the small intestine while Losartan is being
biotransformed in the liver by cytochrome P450 enzymes. Drugs that inhibit the
cytochrome P450 enzymes may interfere with the conversion of Losartan to its
metabolite, possibly decreasing its effectiveness. The systemic bioavailability varies
widely from a low of 13% for Eprosartan to as high as 80% for Irbesartan. Food
alters the bioavailability of both Eprosartan and Valsartan. There is a large variation
in plasma elimination half-life (t1/2) of ARBs where Losartan has a short half-life of
2 hours while Telmisartan has extremely long-half of 24 hours. The antihypertensive
is consistent across ARBs drugs and is within two to four weeks after initiation of
therapy. The mode of elimination of ARBs is predominantly by hepatic route (Unger,
1999; Parnell et al., 2000; Drug Facts and Comparisons, 2001; Rodger & Patterson,
2001; Schwocho & Masonson, 2001).
Several clinical trials have shown the beneficial effects of ARBs therapy that goes
beyond blood pressure control. Firstly, in renal disease, ARBs reduce progression of
proteinuria and the development of end-stage renal disease in patient with
hypertension and renal insufficiency (Brenner & Cooper, 2001; Lewis, 2002; Berl et
al., 2003; Viberti & Wheeldon, 2002). Secondly, ARBs therapy reduces left
ventricular mass and cardiovascular morbidity and mortality in patients with left
ventricular hypertrophy and hypertension (Dahlof et al., 2002). Thirdly, ARBs
protect against stroke (Dahlof et al., 2002; Lithell et al., 2003; Hankey, 2004).
7Fourthly, ARBs play significant role in the treatment of heart failure (Konstam et al.,
2005; Young et al., 2004; Maggioni et al., 2002). Most recently, ARBs have shown
to delay the development of hypertension in prehypertension (Vasan, 2002). The
therapeutic uses of ARBs and dosage adjustments in renal or hepatic impairment
patients (Malaysia Index of Medical Specialities (MIMS) Annual, 2009) are as
summarised in Table 1.2
8Table 1.2: Therapeutic Uses of ARBs
Therapeutic Uses Use inDrug
Diabetic
Nephropathy
Heart Failure
and Left
Ventricular
Dysfunction
Hypertension Hypertension
and Left
Ventricular
Dysfunction
Post
Myocardiac
Infraction
with / without
Left
Ventricular
Dysfunction
Renal Impairment Hepatic
Impairment
Candesartan Yes Yes Yes Adjust dose
(CrCl<30ml/min)
Adjust dose.
Avoid in severe
impairment
Eprosartan Yes No Adjustment Adjust dose.
Avoid in severe
impairment
Irbesartan Yes Yes Adjust dose
(Undergoing
haemodialysis)
No clinical
experience in
severe impairment
Losartan Yes Yes Yes Adjust dose
(CrCl<20ml/min)
Adjust dose
9Table 1.2 (Continued)
Therapeutic Uses Use inDrug
Diabetic
Nephropathy
Heart Failure
and Left
Ventricular
Dysfunction
Hypertension Hypertension
and Left
Ventricular
Dysfunction
Post
Myocardiac
Infraction
with / without
Left
Ventricular
Dysfunction
Renal Impairment Hepatic
Impairment
Olmesartan Yes Not recommended
if CrCl<20ml/min
Avoid use
Telmisartan Yes Not recommended
if CrCl<30ml/min)
Adjust dose.
Avoid in severe
impairment
Valsartan Yes Yes Yes Adjust dose
(CrCl<20ml/min)
Adjust dose.
Avoid in severe
impairment
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In this study, hypertensive drugs were chosen because hypertension is one of the
most prevalent chronic disorders in the country (Lim et al., 2004). The prevalence of
hypertension is high but the level of awareness, treatment and control are low. A
national study on the prevalence, awareness, treatment and control of hypertension
which involved 16,440 subjects and conducted in 2004 (Rampal et al., 2008)
revealed that the prevalence of hypertension among those age 30 years has increased
from 32.9% in 1996 to 40.5% in 2004. Only 34.6% of the hypertensive patients were
aware of their hypertensive status and 32.4% were taking antihypertensive drugs.
Many patients were not on drug treatment at all and of those treated, their drug
treatment are likely to be inadequate as reflected by the study that only about 26.5%
of those on antihypertensive drugs had their blood pressure under control. The
Mortality Country Fact Sheet (World Health Statistics, 2006) showed that
hypertensive heart disease is one of the top ten causes of death, all ages in Malaysia
in year 2002. These results indicate that there is an urgent need to address this
growing problem of hypertension among the Malaysians.
Based on Malaysian Statistics on Medicine (Sameerah & Sarojini, 2005), Malaysia
is third in the top 30 list based on the therapeutic group by utilisation in DDD/1000
population/day 2005 for antihypertensive drugs acting on the renin-angiotensin
system.The total utilisation of antihypertensive was 73.5 DDD/1000 population/day
and Angiotensin II Receptor Blockers (ARBs) was 4.6 DDD/1000 population/day
which worked out to be 22% of the agent acting on renin-angiotensin system. The
low utilisation of ARBs could be due to higher cost and fewer trials supporting a
mortality reduction as compared to Angiotensin Converting Enzyme Inhibitors
(ACEIs) and the availability of alternatives with proven effectiveness.
11
Over the years, most national and international guidelines have not recommended
ARBs as first-line treatment for hypertension as evidence on hard endpoints such as
cardiovascular morbidity and mortality in patients with hypertension was not
available until 2002 (Dahlof et al., 2002). In Malaysia, the Clinical Practice
Guideline (CPG) for the management of hypertension (2008) recommended ARBs in
patients with newly diagnosed uncomplicated hypertension and with no compelling
indications as one of the choices of first-line monotherapy. Beta Blockers are no
longer recommended for first-line monotherapy as it is not as effective in lowering
blood pressure and in the prevention of stroke compared to other antihypertensive
drugs (Lindholm et al., 2005). This updated CPG for the management of
hypertension (2008) also supported the use of ARBs as the first-line therapy for
hypertension in patient with concomitant condition such as diabetes mellitus with
nephropathy, non-diabiatic renal disease, cardiovascular disease and stroke. This
was due to the accumulated evidences of ARBs in reducing the cardiovascular
morbidity and mortality (Hansson et al., 1999; Brown et al., 1999; Wing et al., 2003;
Davis et al., 2002) and also significantly lower morbidity and mortality from further
strokes (Schrader et al., 2005) in addition to effectiveness, tolerability, adherence
profiles and demonstrated benefits in organ protection. Also, there have been no
reports of adverse effects on carbohydrate and lipid metabolism (Parving, 2001;
Brenner, 2001; Lewis, 2001). The utilisation rate of ARBs is expected to increase
with these evidences supporting beneficial effects that extend beyond blood pressure
reduction alone.
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This paper will discuss and highlight in sequence the evaluation of Angiotensin II
Receptor Blockers (ARBs) for drug formulary using an objective Scoring Analytical
Tool (SAT). Generally, the development of the scores allocation for safety, efficacy
and cost criteria and sub-criteria for the ARBs for hypertension leading to the full
questionnaire format and the feedback from selected specialists and non-specialists
participants from selected government hospitals, including complete analysis of
results, discussion and recommendations will be described in detail.
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1.2 Problem statement
Currently, there is no scoring tool that has been developed or even used in Malaysia
which can assist decision-makers at all levels (national, regional, hospital, primary
care) faced with difficult choices about which drugs to make available to their
patients especially those new drugs which offer marginal improvement over existing
therapies but at substantially increased costs. The Ministry of Health (MOH) Drug
List Review Panel will review and update the drug listed in the formulary from time
to time to ensure that a comprehensive, evidence based and dynamic list of drugs is
available for prevention and treatment of patients. They will meet two to three times
per year to evaluate the proposal or requests for addition or deletion of drugs to the
formulary (Malaysian MOH Drug Formulary Manual, 2008). Here, the process of
screening or evaluating the drugs for inclusion or exclusion into the formulary will
take long period depending on the expertise of a handful of senior specialists. A
scoring tool will be a great help as it will enable drugs to be assessed in a more
structured, consistent and reproducible manner and hopefully to overcome biasness
in terms of main drug supplier influence and emotional aspects.
Scoring tool with cut off point score for inclusion of drugs in the drug formulary
will be able to reduce the number of drugs of the same therapeutic class and
subsequently a decrease in hospital inventory. Reducing number of drugs of the
same therapeutic class with only slight differences in clinical effectiveness, adverse
effect or price could be one of the options to lower the overall expenditure. This is
because the cost of all aspects of health care is increasing at an alarming rate. For
example, in Malaysia, the drug expenditure had increase from RM346 million in
year 2000 to RM915 million in 2005. Based on the Annual Report by Malaysian
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Ministry of Health Pharmaceutical Services Division (2005), in year 2004 to 2005,
an increase of 13.3% of drug expenditure was recorded. In Malaysia, the public
health facilities support 80% of the country’s patient population and the drugs made
available for use in the public health care are controlled through the Malaysian
MOH Drug Formulary. It is important that the Malaysian MOH Drug Formulary
have the strategies involving formulary management so as to curb the high drug
expenditure and ensure efficient allocation.
In short, the main problem at large is the insufficient and lacking of available
simplified easy-to-use method to evaluate and carry out rationalised drug selection
which can replace the existing more time consuming conventional or traditional
method like the one being used by the MOH Drug Formulary. Here, it can be seen
that the application of SAT can potentially or prospectively fill this gap. As an
example, SAT can be used to establish whether it is justified to select members of
the drugs belonging to the same therapeutic group. For example, these four ARBs
(Losartan, Telmisartan, Irbesartan and Valsartan) which were selected by our Drug
and Therapeutic Committee can be determined from the order of preference based
on the Final Score of each ARB using SAT. SAT can also be used to determine the
trend of drug use and also whether there is any discrepancy between pattern of drug
use and local clinical guideline recommendation by the drug usage as a means of
relating to the order of preference of the drugs concerned.
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1.3 Rationale of the study
The rationale of this study is to enable drugs for inclusion or exclusion into a
formulary to be assessed in a more objective, free from biasness, consistent and
reproducible manner. The nature of the SAT which is essentially a score allocating
method of evaluating drugs will hasten the whole drug approval or disapproval
process as it is not practical for those involved in the drug evaluation and selection
to delay important decision making especially on life saving drugs. By virtue of this
fact, it will tremendously assist decision-makers at all levels (national, regional,
hospital, primary care) faced with difficult choices about which drugs to make
available to their patients. In fact, it can also help to simplify the whole process.
SAT can also reduce the number of drugs of the same efficacy and safety within the
same therapeutic class as there is no need to include all members of a particular drug
class in a drug formulary especially those new drugs which offer only marginal
improvements over existing therapies but at substantially increased costs (Kessler et
al., 1994).
This scoring tool can be used as a template to evaluate and re-evaluate when the
need for re-assessment arises and also be extended to other classes of drugs. Thus,
this study is justified in that if the tool can be effectively developed, it can be very
useful in improving and speeding up the formulary inclusion or exclusion process in
Malaysia.
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1.4 Research objectives
1.4.1 General objective
The general objective is to develop an objective scoring tool for rational drug
selection into the national drug formulary.
1.4.2 Specific objectives
The specific objectives of this study are:
a) to determine the list of relevant criteria and sub-criteria that can be used to
evaluate the selection of Angiotensin II Receptor Blockers (ARBs) to be
included in the drug formulary
b) to determine the scores for each selected criteria/sub-criteria of Angiotensin
II Receptor Blockers (ARBs) for evaluation
c) to determine the cut off point for selection of Angiotensin II Receptor
Blockers (ARBs) into drug formulary
d) to evaluate cost analysis of Angiotensin II Receptor Blockers (ARBs) by
using ratio of drug acquisition cost to score of quality criteria
e) to compare the prescribing pattern of Angiotensin II Receptor Blockers
(ARBs) in Serdang Hospital, Selangor with the order of preference of ARBs
based on Final Score of ARBs using Scoring Analytical Tool (SAT)
f) to examine the prescribing pattern of Angiotensin II Receptor Blockers
(ARBs) in Serdang Hospital, Selangor as first-line and second-line treatment
of hypertension.
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1.5 Significance of the study findings
The study on utilising SAT involved essentially developing relevant criteria and sub-
criteria pertinent to individual specific Angiotensin II Receptor Blockers (ARBs)
and correspondingly allocating the scores for each selected criteria and sub-criteria
of the ARBs concerned and eventually subjecting for evaluation via statistical means.
The results so obtained strongly showed that SAT is indeed a very useful tool which
just employs scores to evaluate and simplify evaluation of drugs for decision making.
It is clear that the existing ways of decision making is more qualitative and
experiential-based and time consuming. Taking MOH for instance which a handful
of senior expert specialists presides periodically to decide what drugs to select or
omit for drug formulary inclusion. Envisaging using SAT, the decision process
would be reduced tremendously. The Drug and Therapeutics Committee at hospital
level can use SAT as a guide for selection of drug for hospital formulary. The data
collected from SAT can be used to identify general prescribing and design
appropriate interventions and to measure the impact of these interventions on the
drugs use. The doctors especially the non-specialists who are not involved in the
decision making in the Drug and Therapeutics Committee have the opportunity to
evaluate the selected drug for the hospital formulary and voiced their opinions. SAT
can also reduce the number of drugs of the same efficacy and safety within the same
therapeutic class in our MOH Drug Formulary. This will enable the Pharmacy Store
to reduce drug inventory or reduction in the number of drugs purchased and hence
results in lower overall expenditures. The drug allocation or fund can be used to buy
other safe and effective drugs. Here, the patients also benefit in terms of lower
medication costs and drugs available are more safe and effective. Healthcare
professionals can by using such tool to evaluate drugs and the results thus obtained
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can be used to advise the patients on the side effects, effectiveness, etc. Even
insurance companies, for example, can be specific about what drugs or medication
that when prescribed may incur higher premiums by merely having more side effects.
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CHAPTER TWO
LITERATURE REVIEW ON THE SCORING ANALYTICAL TOOLS
2.1 Introduction
Development of a Scoring Analytical Tool or SAT to rationalise a large number of
drugs available with a view to shortlist essential medicines, control costs and
improve prescribing practices requires essentially an objective, transparent and free-
from external influence environment. This tool that is so developed would be re-
evaluated or re-assessed from time to time and made available for use to the medical
community in general. This tool is essentially being formulated with a main purpose
of fine-tuning the means of evaluating drugs in a manner that is not biased.
Generally, many countries are using formularies principle for drugs selection.
According to Woodhouse (1994), the main aims of a formulary are to encourage
clinically effective and cost effective prescribing, to restrict the range of medicines,
allowing prescribers to increase their familiarity with a smaller number of medicines,
encourage generic substitution, prevent relatively untried medicines getting into
widespread use and aid cost containment. Woodhouse also suggested that medicines
should be chosen for inclusion in a formulary on the basis of their relative proven
efficacy, favorable risk-benefit ratio and cost. Some conventional formulary models
that will be touched on like Malaysian Ministry of Health (MOH) Drug Formulary
and World Health Organisation (WHO) Drug Formulary as well as other recent
methods which include Pharmaceutical Product Drug Differentiation Evaluation
Model or PPDDEM (Karr, 1994), Comparative Utilisation of Resources Evaluation
Model or CURE Model (Karr, 2000), System of Objectified Judgment Analysis or
SOJA (Janknegt & Steenhoek, 1997) and Ranking Model (Bochner et al., 1994).
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The main purpose of this literature review is to critically evaluate the proposed
developed scoring tool by comparing similarities and differences among the
available established methods. Each of the published methods will be discussed in
detail and the similarities and differences will also be dealt with and eventually
leading to the justification of the development of SAT and the scope of its
application.
2.2 Drug formulary
The traditional and conventional as mentioned earlier generally employs formulary
system involving such a method whereby the medical staff of an institution, working
through a Drug and Therapeutics Committee, manages, evaluates and selects from
the numerous available drug products that are considered most efficacious, safe, and
cost effective (Savelli et al., 1996). Initially, at the health facility level usually
ministerial, an authoritative body, known as the Drug and Therapeutics Committee,
must be established to be held responsible for all aspects of the formulary system,
including drawing up policies and procedures for selection and use of drugs,
compiling drug information, designing and conducting on-going monitoring and
evaluation programs that ensure proper use of drugs in the facility. The result of
such drug selection process is a drug formulary list. The list contains all drugs
approved for procurement and used in a given health facility.
Well established formularies are useful reference or tools in helping solve problems
of drug therapy, namely providing impartial drug information to counteract biased
promotional activities. At present, as many as 70% of the pharmaceuticals on the
